Abbott plans to spin out its nutrition business

Abbott plans to spin off its nutrition business, which has $8.5B annual sales, into a separate publicly traded company by late 2027. The move aims to focus on higher-growth markets. Abbott's Q3 revenue was $13.01B, with nutrition contributing $2.26B. The spinout is not expected to impact 2026-2027 guidance. Abbott faces ongoing litigation related to its nutrition business.

Original reporting
Published Oct 21, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Abbott plans to spin out its nutrition business — source image
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The spinout is expected to improve Abbott's margin profile and focus, while the new nutrition company will inherit both revenue streams and ongoing legal exposures.

02

Market read

A major restructuring of a large‑cap healthcare company that could reshape earnings expectations and sector dynamics.

03

What to watch

Regulatory approval timeline and the ability of the new company to secure independent financing may affect the ultimate value creation.

Relevance 7/10Novelty 8/10Timing: announced today

Background

Abbott's nutrition segment has faced litigation and a DOJ settlement, prompting a strategic decision to separate it from the core medical business.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott announced a plan to spin out its nutrition business into a separate publicly traded company, a first‑time disclosure of a major corporate restructuring.

Expected impact

modest upside for ABT as investors price in higher margins and a clearer growth narrative

Evidence & confidence

The nutrition unit accounts for $2.26B Q3 revenue with margins below corporate average; its removal should lift earnings per share and reduce litigation risk, supporting a bullish view.

Market effects

May prompt other med‑tech firms to consider similar spinouts of low‑margin consumer segments.

U.S. healthcare and consumer health sectors could see re‑rating as focus shifts to higher‑margin medical devices and diagnostics.

Limited to investors tracking large‑cap U.S. healthcare stocks; no immediate global macro effect.

Counterpoint

The spinout could create short‑term volatility and valuation uncertainty for the new nutrition entity, potentially dragging down the parent if execution stalls.

Key entities

  • Abbott Laboratories

    U.S. healthcare conglomerate planning the spinout.

  • Robert Ford

    CEO of Abbott, quoted on the strategic rationale.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.